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ABSTRACT  
Background: Peanut allergens are common responsible of food allergy. Analyses of 
sensitization patterns, relationships with other allergens, clinical symptoms and 
variation with age are needed. We studied sensitization to Ara h 2, Ara h 9 and Pru p 3 
in a population of children/adolescents allergic to peanut, and the relation with peach 
and pollen.   
Methods: Patients allergic to peanut were classified into two groups: A) allergic to 
peanut, and B) allergic to peach and peanut. The IgE response was measured to Ara h 2, 
Ara h 9 and Pru p 3. 
Results: Of 456 subjects evaluated, 28% were allergic to peanut. From this group 69% 
were sensitized to pollen. Urticaria was the most frequent entity followed by 
anaphylaxis and OAS. Fifty-nine percent had Ara h 2 and/or Ara h 9 specific IgE. Over 
half reported symptoms with peanut alone (Group A); 46% to peanut and peach (Group 
B). We observed significant differences in sex, age, onset of symptoms and sensitization 
to Artemisia. IgE response to Ara h 2 was more frequent in Group A; Ara h 9 and Pru p 
3 in Group B. We observed a decrease in sensitization to Ara h 2 and an increase to Ara 
h 9 and Pru p 3 with increasing age. 
Conclusion:  Peanut allergy is frequent in subjects with allergy to plant-foods, with Ara 
h 2 and Ara h 9 being two important allergens. In younger patients Ara h 2 
predominates over Ara h 9. The reverse was observed in older patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
INTRODUCTION 
The prevalence of food allergy varies between 1% and 3% in the general population and 
is on the rise (1-4). Immediate reactions to food of plant origin are one of the most 
frequent causes of food allergy, with many cases starting in infancy (5,6). Peanut 
allergens are frequently implicated, affecting 1% of the population (7). Several studies 
have reported an allergy prevalence rate of 0.50%-1.85% in children (1,8).  However, 
more studies need to be undertaken in other populations and with larger age ranges. 
The major peanut allergens Ara h 1, Ara h 2 and Ara h 3 are vicilin, conglutin (2S 
Albumin) and legumin seed storage proteins (SSP), respectively (9-14). Ara h 8 is a 
pathogenesis-related protein, PR-10 (15,16); Ara h 9 belongs to the lipid transfer protein 
(LTP) family, many of which are important allergens in the Mediterranean area (17-19). 
Many plant allergens are panallergens, present in many different sources. They are 
responsible for the cross-reactivity between homologous proteins from plant-derived 
foods and pollens (20-22). In central European countries a strong association exists 
between pollen sensitisation and food allergy. For example, apple and peach 
sensitization has been associated with primary sensitization to Bet v 1, the major birch 
pollen allergen, as well as Mal d 1 or Pru p 1, all belonging to the PR-10 family (23). 
Other associations between pollen and plant-derived foods have been described, along 
with details of the responsible allergens (24,25). This situation varies in the 
Mediterranean area where sensitization to Pru p 3 (LTP from peach) has been shown to 
be unrelated to pollen allergies (26,27).   
Values of specific IgE to single molecular allergens may vary according to age. For 
example, peanut allergic children and adults have shown differences in allergen 
molecular recognition, with Ara h 2 the most prevalent in children (28) and Ara h 9 in 
adults (18). It is known that Ara h 9 sensitization is due to cross reactivity with Pru p 3, 
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both LTPs (19,29). However, the reasons for the age-related differences in allergen 
recognition are complex and cannot be explained in term of allergen exposure and the 
cross-reactivity phenomenon only. Detailed studies of how these patterns of 
sensitization occur at different ages in the same population and the relationship with 
related foods/inhalants are needed. This is particularly relevant in populations where 
primary sensitization occurs through the oral route. 
In order to verify these variations in the molecular response to plant food allergens we 
undertook a cross-sectional study in a population ranging from 1 to 20 years of age. 
This provides a clearer view of sensitization patterns in different age groups. Those 
confirmed as allergic to peanut were further studied in order to verify the role of major 
peanut and peach molecular allergens in inducing sensitization and symptoms. Results 
indicate that the predominate allergen differs according to age: Ara h 2 for younger 
children and Ara h 9 for older children and adolescents. These findings have important 
clinical consequences.  
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MATERIAL AND METHODS 
Subject selection 
All patients were aged between 1 and 20 years old and referred to our service with 
suspicion of food allergy of plant origin were included in our study. The area of study 
was Madrid, Central Spain. All participants completed a written informed consent and 
the ethical committee of our institution approved the study. 
The allergological evaluation included an examination of the patient’s clinical history 
with implementation of an exhaustive questionnaire and skin prick test (SPT) as 
detailed below. In subjects with unclear history, double-blind-placebo-controlled food 
challenge (DBPCFC) was carried out. 
The SPT was performed according to European guidelines (30) using a standardized 
panel of relevant inhalant allergenic extracts that included Phleum, Olea, Platanus, and 
Artemisia pollens plus peach and peanut from ALK-Abelló (Madrid, Spain). The SPT 
response was considered positive if the diameter of the wheal area was 3 mm greater 
than that induced by the negative control. 
Patients were considered allergic if their clinical history showed at least two convincing 
reactions in their history within the first hour after exposure. In those with clear clinical 
history but only one episode to peanut, DBPCFC was performed to confirm the 
diagnosis. DBPCFC was performed as described previously (31). Briefly, meals 
containing 5g of amount of flour peanut with a mixture of yogurt, orange juice, dried 
coffee and oatmeal flakes were prepared. Placebo meals consisted of the same 
ingredients, without peanut. If cutaneous and/or respiratory symptoms or alterations in 
vital signs appeared, the procedure was stopped and the symptoms were evaluated and 
treated (32). We excluded subjects with pathologies such as genetic, autoimmune and 
metabolic diseases. 
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Quantification of IgE antibodies to whole peanut and peach extract and allergens 
Specific IgE antibodies to whole peanut and peach extract and allergens Ara h 2, Ara h 
9 and Pru p 3 were measured by ImmunoCAP following the manufacturer´s 
recommendations (Phadia, Uppsala, Sweden). A positive result was defined as a value > 
0.35 kUA/l.  
Statistical analysis 
Quantitative variables are shown as median and interquartile ranges (IR), while 
qualitative variables are shown as frequencies. Medians between groups were compared 
using Mann-Whitney or Kruskal-Wallis tests, while χ2 was used to compare 
proportions. Differences with a p<0.05 were considered significant. 
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RESULTS 
Characteristics of peanut allergic patients 
We evaluated a population of children and adolescents ranging from 2 to 20 years old 
who reported symptoms after peanut intake and/or contact. After proving 
hypersensitivity we studied peanut allergy in the context of sensitization to other 
relevant allergens including food and inhalants. We established the relationship between 
them by focusing on three relevant allergens in our population: Ara h 2, Ara h 9 and Pru 
p 3.  
From the total number of 456 cases allergic to plant foods initially evaluated, 28% (128 
cases) of the patients reported symptoms with peanut, 260 showed tolerance to peanut 
and the remaining 68 subjects had not had previous contact with peanut. Of the 128 
patients with reported symptoms, 120 were confirmed as hypersensitive to peanut. Of 
these, 91 were diagnosed by clinical history and positive skin prick test and 29 by 
DBPCFC. The remaining 8 cases had good tolerance in spite of reported symptoms 
after peanut ingestion in their clinical history and were not used for further study. The 
median age of peanut hypersensitive patients was 9.86 (IR:2-20) years and 55% were 
male. Skin test response to inhalant allergens was positive for 96% of the cases, with 
69% sensitive to pollens. The majority of patients (88%) had other allergic diseases in 
addition to food allergy. These were atopic dermatitis (63%), rhinoconjuntivitis (68%) 
and asthma (51%). The clinical symptoms most frequently reported by the patients was 
urticaria/angioedema in 58 patients (48%), followed by anaphylaxis (dyspnea, wheeze 
and hypotension) in 33 (28%) and OAS in 29 (24%).  
Detailed analysis of these patients showed that 42 were also allergic to peach. The 
clinical symptoms reported by these patients were: OAS in 20 patients (48%), 
urticaria/angioedema in 18 (42%) and anaphylaxis in 4 (9%).  
 9 
Skin prick test results 
Most patients (91%) showed positive skin prick test results to peanut. More detailed 
analysis of these results showed that 90% of patients with anaphylaxis were skin test 
positive to peanut, as were 89% of patients with urticaria/angioedema. For patients with 
OAS, 79% of patients were skin test positive to peanut. Out of the 11 patients with 
negative SPT, 4 had urticaria/angioedema, 4 had OAS and 3 cases had anaphylaxis. 
With respect to pollen allergy, 87% of peanut allergic subjects were positive for 
Phleum, 76% for Olea, 73% for Platanus and 45% for Artemisia. 
Specific IgE results 
From 120 patients studied, 83% had specific IgE to whole peanut extract. When we 
measured specific IgE to whole peach extract to patients allergic to peanut and peach we 
observed that 90% of these had specific IgE to peach extract. 
Measuring IgE response to peanut allergens showed that Ara h 2 antibodies were 
detected in 33% of patients and Ara h 9 in  42% (Figure 1A). Considering cases with 
specific IgE to only one allergen, 18% were positive to Ara h 2 and 27% to Ara h 9 
only. Out of all peanut allergic patients tested, 59% were positive to at least one allergen 
(Figure 1B).  
Of the patients with positive SPT to peanut, 68% showed IgE antibodies and of the 11 
cases with negative SPT, 7% had IgE antibodies.  
The proportion of patients with specific IgE to Ara h 2 and Ara h 9 was similar for 
patients with anaphylaxis and urticaria. For OAS, a higher proportion of patients 
showed IgE to Ara h 9 (48%) compared to Ara h 2 (24%) (Figure 2).  
Comparison between peanut allergic patients with tolerance to peach and patients 
allergic to both peanut and peach. 
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In order to establish the relationship between peanut and peach allergy we compared the 
results in those patients with allergy to peanut but tolerant to peach (Group A, N=64) 
and those with symptoms induced by both peanut and peach (Group B, N=42)   (Table 
1). Those subjects who never took peach (N=14) were removed from this analysis. The 
patients of Group A were younger and the symptoms appeared earlier than in Group B. 
The overall pollen sensitization in Group A was lower than in Group B, but if we 
analyzed this response considering the pollens individually we detected that Phleum, 
Olea and Platanus were similar between both groups, however the percentage of 
Artemisia was significant higher (p=0.033) in Group B. Significant differences were 
observed between groups for patient age, age at symptom onset, sex, IgE specific to 
peach and sensitization to pollens.  
When we compared the clinical symptoms induced, anaphylaxis appeared in 31% of the 
cases in Group A and in 19% of Group B (p=0.014), urticaria/angioedema was similar 
for both (52% in Group A and 44% in Group B). OAS was more common in Group B 
with 37% compared to 15% of Group A (p=0.022) (Figure 3). 
The IgE response to individual peanut and peach allergens was analysed. When we 
compared Group A and Group B, we observed the number of individuals with IgE to 
Ara h 9 and Pru p 3 was significantly higher (p=0.001 and p=0.008, respectively) in 
Group B. Within Group A, Ara h 2 was the most frequent allergen, although this 
difference did not reach statistical significance. Within Group B Ara h 9 and Pru p 3 
were significantly more prevalent than Ara h 2 (p=0.003 and p=0.012, respectively) 
(Figure 4). 
When taking into account combinations of allergens we found that for Group A the 
cases positive to Ara h 2 were the most frequent (p=0.050) followed by the combination 
of Ara h 2, Ara h 9 and Pru p 3. Very few cases showed IgE to the combination of Ara h 
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9 and Pru p 3 only. On the other hand, for cases with allergy to both peanut and peach, 
the highest number of positive results corresponded to the combination of Ara h 9 and 
Pru p 3 (p=0.018) only; few cases were found that were positive to Ara h 2 only (Table 
2). 
Differences in the recognition of peanut and peach allergens according to age 
We grouped patients by age intervals of 5 years from youngest to oldest in order to 
evaluate differences in the IgE response to Ara h 2, Ara h 9 and Pru p 3 (Figure 5). We 
observed that values of specific antibodies showed a significant decrease of Ara h 2 
allergen prevalence with increasing age (Figure 5A). In contrast, the number of patients 
with antibodies to Ara h 9 and Pru p 3 increased with age (Figure 5B, 5C). We conclude 
that Ara h 2 positivity was much more prevalent in young children than Ara h 9 and Pru 
p 3. However the opposite was observed for older age groups. 
 12 
DISCUSSION 
In this work we have performed a cross-sectional study in a large group of children and 
adolescents with allergy to plant foods in a centre located in central Spain (Madrid). 
More than a quarter of patients reported symptoms with peanut, in agreement with 
previous studies in a similar population (3,34,35). We also observed association with 
other allergic diseases such as atopic dermatitis and asthma, as reported previously (36). 
Reactions to plant allergens are highly associated with pollen allergy (20,21,37). In our 
population we observed a variable percentage of sensitization to the pollens tested with 
Phleum, Olea and Platanus higher that 50%.  Whether this association is related to 
cross-reactivity or represents a clinical property of atopic patients is a matter of 
speculation, however all these pollens contain panallergens with similar structures to 
peanut and peach proteins, such as profilins, PR-10 and LTPs. Focusing on the pollens 
with LTP allergens, we observed a strong association between patients allergic to both 
peanut and peach as food sources, and Artemisia pollen, suggesting cross-reactivity 
across LTP proteins (38-39). 
Considering the clinical symptoms, over three quarters of peanut allergic patients 
observed in the study developed systemic symptoms, and more than a quarter developed 
anaphylaxis. These findings are similar to those reported by Pedrosa (28), where 
urticaria/angioedema was the most frequent clinical symptom followed by OAS and 
anaphylaxis. 
The diagnosis of peanut allergy in our study was largely based on an unequivocal 
history of several episodes after ingestion of peanut. We detected that SPT was positive 
to peanut in 91% of these patients and 83% of them had specific IgE antibodies to 
peanut. Similar results have been described in other studies (40). For patients with 
anaphylaxis, 95% were SPT positive, and 75% had detectable IgE antibodies to 
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allergens peanut. For urticaria/angioedema 89% were SPT positive and 66% had 
detectable IgE antibodies. For those patients with OAS, 88% had a positive SPT and 
76% had detectable IgE antibodies. Interestingly, we detected IgE antibodies to purified 
allergens for 7% of the cases that produced a negative SPT. This result may be due to a 
low concentration of the relevant allergen in the whole extract used for SPT, as 
suggested by others (41). 
Regarding the sensitization profile to peanut allergens, we found that 42% of patients 
had IgE to Ara h 9, and 27% of the patients were monosensitized to this allergen.  
A third of all patients recognized Ara h 2 and 18% were monosensitized. Our results are 
in line with a recent study from Calamelli (42) but are lower than those of Vereda et al 
(19). More than half (59%) of all patients had IgE antibodies to at least one allergen. 
Ara h 9 is more prevalent in the population studied here and appears to play an 
important role in peanut allergy among patients from the Mediterranean area (17,18). 
Ara h 2 has been implicated in other populations (28,43-45). For example, the work of 
Vereda et al. (19) showed that Ara h 2 was recognised by 42% of patients with peanut 
allergy. 
Our study revealed an age dependent sensitization pattern in patients allergic to peanut 
extract. Interestingly, we found that the youngest group of children were more 
frequently monosensitized to Ara h 2: 32% at 1-5 years and 20% at 6-10 years. 
However the opposite pattern was found for Ara h 9: no patients in the 1-5 year group 
were monosensitized, however for 6-10 year old subject, 36% were monosensitised. 
Similar results have been described in a recent study where levels of IgE to Ara h 2, Ara 
h 8, Ara h 9 were measured in a pediatric population (42). It seems that natural loss of 
sensitisation occurs to Ara h 2 with increasing age, while awareness of LTP is gradually 
beginning. The presence of members of the LTP family in many species could be like a 
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maintenance dose of the allergen for these individuals. However, the absence of cross 
reactivity between 2S albumins due to the high difference in the primary structure of 
these proteins may lead a reduction in the allergic response to the allergen (46).  
Regarding the relationship between clinical symptoms and the pattern of allergen 
recognition, fewer patients with OAS had IgE against Ara h 2 than Ara h 9. However, 
we did not find any differences for anaphylaxis or urticaria/angioedema. Our data agree 
with previous studies (28,47), although one study has shown anaphylaxis to be more 
highly associated with Ara h 2 (48). 
The association of peach and peanut allergy is high in the Mediterranean region, due to 
cross-reactivity between both peanut and peach LTP (49). However this relation is less 
marked in other countries as described previously (19). So, our population could be 
divided into two major groups: patients with allergic reactions to peanut and not peach 
(Group A), and patients with allergic reactions to both peanut and peach (Group B) as 
described previously (29,49,50). Almost one third of the peanut allergic patients 
belonged to Group B. Symptoms with peach often appeared before peanut allergy. This 
may be due a primary sensitization to peach LTP, Pru p 3, as previously reported by our 
group in an adult population (29).  Sensitization to pollen was higher in patients allergic 
to peanut and peach than in those only allergic to peanut, especially for Artemisia. This 
could be due to cross-reactivity between pollen and food as described previously 
(39,51).   
Analysis of the sensitization pattern confirmed that allergen recognition differed 
between groups. In Group A, Ara h 2 was higher than Ara h 9 or Pru p 3 (peanut and 
peach LTPs). In Group B, Ara h 9 and Pru p 3 were significantly higher. These findings 
agree with other studies (17,18,45,47,50). However, only 22% of cases from Group A 
had systemic reactions (anaphylaxis and urticaria/angioedema) and only 12% of Ara h 2 
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positive cases Ara h 2 from Group B had systemic reactions. In 10% of cases in Group 
A, the subject had IgE antibodies to Ara h 2 and Ara h 9. Because these subjects 
developed symptoms to peanut only and tolerated peach, we conclude that Ara h 2 was 
responsible for the symptoms.  
For some cases in Group B, specific IgE was detected for Ara h 9 but not Pru p 3, 
indicating that Ara h 9 can be the primary sensitizing agent. Ara h 9 has been described 
as the primary sensitizer in adults (29). 
Summarizing, our study presents the largest series of child and adolescent peanut 
allergic patients and suggests that the sensitization profile is related to sensitivity to 
other foods and pollen. Moreover, the proportion of patients with specific IgE 
antibodies varies according to age: for older children and adolescents, fewer patients 
show IgE to the Ara h 2, whilst more patients show IgE to the LTP proteins Ara h 9 and 
Pru p 3. 
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Table 1. Comparison of demographic and clinical characteristics of patients with 
symptoms to peanut and tolerance to peach (Group A) and patients with symptoms to 
peanut and peach (Group B). Significant differences (P<0.05) are indicated in bold. 
 
 
  
SYMPTOMS TO  
PEANUT AND 
TOLERANCE TO 
PEACH 
 (N=64) 
 
 
SYMPTOMS TO 
PEANUT AND 
PEACH 
 (N=42) 
P 
 
Age, median (IR) 
 
 
8.77 (2-20) 
 
11.87 (2-20) 0.010 
 
Age at onset of symptoms, 
median (IR) 
 
            5.71 (1-17) 
 
Peanut: 8.45 (1-19) 
Peach: 6.68 (1-19) 
 
0.016 
 
Sex, % Male 
 
 
63 
 
 
38 0.020 
 
Caucasian, % 
 
 
86 
 
91 0.559 
Specific IgE, % 
     Peanut whole extract 
     Peach whole extract 
 
 
80 
61 
 
93 
93 
0.145 
0.003 
 
Atopy, % 
 
 
95 
 
84 0.324 
 
Sensitization to pollen, % 
      Phleum 
      Olea 
      Platanus 
      Artemisia 
 
 
61 
93 
70 
73 
33 
 
84 
82 
82 
79 
57 
 
0.031 
0.156 
0.301 
0.660 
0.033 
 
 
Associated Allergic 
Diseases, % 
 
 
86 
 
91 0.559 
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Table 2. Comparison of percentages of positive cases to single or to combinations of 
allergens Ara h 2, Ara h 9 and Pru p 3 for patients with symptoms to peanut and 
tolerance to peach (Group A) and patients with symptoms to peanut and peach (Group 
B). Significant differences (P<0.05) are indicated in bold. 
  
SYMPTOMS TO  
PEANUT AND 
TOLERANCE 
TO PEACH 
 (N=64) 
 
 
SYMPTOMS TO 
PEANUT AND 
PEACH 
(N=42) 
p 
Ara h 2 20% 9% 0.050 
Ara h 9 2% 6% 0.564 
Pru p 3 0% 3% 1 
Ara h 9 + Pru p 3 6% 44% 0.018 
Ara h 2 + Ara h 9 2% 3% 1 
Ara h 2 + Pru p 3 2% 0% 1 
Ara h 2 + Ara h 9 + Pru p 3 16% 9% 0.132 
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FIGURE LEGENDS  
 
Figure 1.- Percentage of positive cases to peanut allergens (Ara h 2 and Ara h 9) in the 
population reporting symptoms to peanut (measured by ImmunoCAP). A)  IgE response 
to peanut allergens Ara h 2 and Ara h 9. B) IgE response to single peanut allergens (Ara 
h 2 + Ara h 9 - , Arah 2 – Arah 9 +) and to any or both allergens (Ara h 2 + and/or Ara h 
9 +). 
Figure 2.- Percentage of positive cases to peanut allergens (Ara h 2 and Ara h 9) for 
patients presenting different clinical symptoms in the population reporting symptoms to 
peanut (measured by ImmunoCAP). 
Figure 3.- Differences between clinical symptoms developed by ingestion and/or 
contact to peanut in patients with symptoms to peanut and tolerance to peach (Group A : 
N=64) and patients with symptoms to peanut and peach (Group B : N=42). P<0.05 
represents a significant difference. 
Figure 4.- Percentage of positive cases to peanut and peach allergens (Ara h 2, Ara h 9 
and Pru p 3) in patients with symptoms to peanut and tolerance to peach (Group A : 
N=64) and patients with symptoms to peanut and peach (Group B : N=42). P<0.05 
represents a significant difference. 
Figure 5.- Percentage of positive cases showing specific IgE (A,B,C) to peanut and 
peach allergens (Ara h 2, Ara h 9 and Pru p 3) in patients, grouped by age intervals of 5 
years from youngest to oldest. P<0.05 represents a significant difference. 
 
 
 
 
 
 
 
 
 
 





